Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of CVL-231 MR and IR formulations in healthy participants
NCT05106309Phase 1Completed
- Sponsor
- Cerevel Therapeutics
- Start
- Dec 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of emraclidine in schizophrenia (2 arms), sponsored by Cerevel Therapeutics. Primary endpoints: Peak Plasma Concentration up to 72 Hours, Time to Maximum Concentration up to 72 Hours and 7 more. Started Dec 2021; status: completed.
02
Drugs
emraclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT05106309.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05106309.